Zoetis (ZTS) Q3 FY25 earnings call

Earnings call· Sep 2025 (Q3 FY25)· Health Care· Nov 4, 2025

Source: earnings call transcript

Zoetis reported moderated Q3 FY25 growth, with 4% organic operational revenue growth and 9% adjusted net income growth, impacted by strong prior-year comparisons and declining therapeutic vet clinic visits. Despite near-term macro headwinds and competitive dynamics affecting key franchises like OA pain and dermatology, the company remains confident in its diversified portfolio, market-leading innovation, and robust pipeline, which continues to advance new products like Lenivia and Portela. Management is implementing strategic adjustments and cost discipline to sustain profitability and long-te

You’re reading a preview. Opening the full call uses 1 concall credit.

ZTS operating KPIs by quarter

ZTS operating KPIs stated on its earnings calls, by fiscal quarter
KPI	Dec 2024 Q4 FY24	Jun 2025 Q2 FY25	Change vs prior quarter
Patients Librela	1.2M+ Librela, now entering its second year in the market, generated $53 million, growing 21% on the quarter and reaching more than 1.2 million patients. Source: earnings call transcript	1M And today, we are reaching just 1 million of them. Source: earnings call transcript	—

Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.

Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.